ERN1 and melanoma: 17-Aminogeldanamycin is a more potent HSP90 inhibitor than geldanamycin against melanoma cells, and exerts previously unidentified activities including diminution of self-triggered upregulation of HSP70 expression and selective inhibition of cytoprotective IRE1α-XBP1s axis of unfolded protein response.